PB2012: A PHASE 2 MULTIARM STUDY OF MAGROLIMAB COMBINATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

• B. Paul,
• M. Liedtke,
• D. S. Siegel,
• J. Khouri,
• J. Hillenglass,
• R. Rifkin,
• M. D. Gandhi,
• A. Kin,
• M. Y. Levy,
• A. Mohrbacher,
• W. Schmidt,
• R. Silbermann,
• F. Cottini,
• D. W. Sborov,
• R. Walker,
• M. Murphy,
• L. Gu,
• A. Chen,
• N. Rajakumaraswamy,
• S. Z. Usmani

Affiliations

B. Paul

1 Levine Cancer Institute, Charlotte

M. Liedtke

2 Stanford Cancer Institute, Stanford

D. S. Siegel

3 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack

J. Khouri

4 Cleveland Clinic, Cleveland

J. Hillenglass

5 Roswell Park Comprehensive Cancer Center, Buffalo

R. Rifkin

6 The US Oncology Network, Denver

M. D. Gandhi

7 Fairfax Office, Virginia Cancer Specialists, Fairfax

A. Kin

8 Barbara Ann Karmanos Cancer Institute, Detroit

M. Y. Levy

9 Baylor University Medical Center, Dallas

A. Mohrbacher

10 University of Southern California, Los Angeles

W. Schmidt

11 Bend Memorial Clinic, Bend

R. Silbermann

12 Oregon Health & Science University, Portland

F. Cottini

13 The Ohio State University Comprehensive Cancer Center, Columbus

D. W. Sborov

14 Huntsman Cancer Institute, University of Utah, Salt Lake City

R. Walker

15 Gilead Sciences, Inc., Foster City

M. Murphy

15 Gilead Sciences, Inc., Foster City

L. Gu

15 Gilead Sciences, Inc., Foster City

A. Chen

15 Gilead Sciences, Inc., Foster City

N. Rajakumaraswamy

15 Gilead Sciences, Inc., Foster City

S. Z. Usmani

16 Memorial Sloan Kettering Cancer Center, New York City, United States of America